SCHEMBL13087449

SCHEMBL13087449

CS(=O)(=O)N1CCC(Sc2cc(-c3cccc(C#N)c3)cc3ccncc23)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNT1 O60563 1/20 0.41
CDK9 P50750 1/20 0.41
VCP P55072 2/20 0.40
CYP11B1 P15538 3/20 0.39
CYP11B2 P19099 3/20 0.39
MCHR1 Q99705 3/20 0.38
SLC22A12 Q96S37 1/20 0.37
NPY5R Q15761 1/20 0.36
HSD11B1 P28845 1/20 0.36
CYP3A4 P08684 1/20 0.35
HPGD P15428 1/20 0.35
MAPK1 P28482 1/20 0.35
HIF1A Q16665 1/20 0.35
IKBKB O14920 1/20 0.35
CHUK O15111 1/20 0.35
MAP4K1 Q92918 1/20 0.35
SCN9A Q15858 1/20 0.35
DHFR P00374 1/20 0.35
THRB P10828 1/20 0.35
WNT1 P04628 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13090022 0.91 VCP (0.38) CCNT1CDK9VCPCYP11B1CYP11B2
SCHEMBL3632369 0.85 SLC22A12 (0.40) VCPCYP11B1CYP11B2SLC22A12CYP3A4
SCHEMBL2426906 0.83 CLK4 (0.42) VCPCYP11B1CYP11B2SLC22A12CYP3A4
SCHEMBL2424533 0.82 ROCK2 (0.43) CCNT1CDK9MCHR1NPY5RDYRK1A
SCHEMBL13087718 0.82 IKBKB (0.46) CCNT1CDK9MCHR1NPY5RIKBKB
SCHEMBL2486778 0.82 GPR119 (0.45) SLC22A12IRAK4
SCHEMBL13087338 0.80 CCNT1 (0.40) CCNT1CDK9CYP11B1CYP11B2MCHR1
SCHEMBL13087253 0.79 IKBKB (0.46) CCNT1CDK9VCPCYP11B1CYP11B2
SCHEMBL13087361 0.79 ROCK2 (0.46) CCNT1CDK9MCHR1NPY5RDYRK1A
SCHEMBL13087305 0.79 ROCK2 (0.46) CCNT1CDK9MCHR1NPY5RDYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8299055-B2 8-substituted isoquinoline derivative and the use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2012-10-30 US disclosed
US-8299055-B2 8-substituted isoquinoline derivative and the use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2012-10-30 US disclosed
US-20100261701-A1 8-Substituted isoquinoline derivative and the use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2010-10-14 US disclosed
US-20100261701-A1 8-Substituted isoquinoline derivative and the use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2010-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261701-A1 8-Substituted isoquinoline derivative and the use thereof RELA, NFKBIA, NFKB2 CCNT1 727/4885CDK9 1157/4885VCP 4302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.